Colorectal Cancer Therapeutics strategies and Product Pipeline Review 2017

Pune, India, 13th October 2017: WiseGuyReports announced addition of new report, titled “Colorectal Cancer Drug Development Pipeline Review, 2017”.

Pune, India - October 13, 2017 /MarketersMedia/ —

Summary
This report provides an overview of the colorectal cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for anal, rectal and colorectal cancer, and features dormant and discontinued projects.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385276-colorectal-cancer-drug-development-pipeline-review-2017

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting.

Finally, colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason.

The size of these pipelines ranges from 10 products in rectal cancer to 581 products in colorectal cancer. Across all three of these indications, however, kinases, immune-related proteins, DNA-related proteins and viral proteins are common targets, closely reflecting the current treatment landscape of these diseases.

Scope
- Which companies are the most active within the pipeline for colorectal cancer therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of colorectal cancer?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 11
2.1 Colorectal Cancer Report Coverage 11
2.2 Anal Cancer - Overview 11
2.3 Rectal Cancer - Overview 11
2.4 Colorectal Cancer - Overview 11
3 Therapeutics Development 12
3.1 Anal Cancer 12
3.2 Rectal Cancer 16
3.3 Colorectal Cancer 18
4 Therapeutics Assessment 56
4.1 Anal Cancer 56
4.2 Rectal Cancer 63
4.3 Colorectal Cancer 71
5 Companies Involved in Therapeutics Development 100
5.1 Anal Cancer 100
5.2 Rectal Cancer 108
5.3 Colorectal Cancer 114
6 Dormant Projects 241
6.1 Anal Cancer 241
6.2 Rectal Cancer 241
6.3 Colorectal Cancer 242
7 Discontinued Products 261
7.1 Anal Cancer 261
7.2 Colorectal Cancer 261
8 Product Development Milestones 265
8.1 Anal Cancer 265
8.2 Rectal Cancer 278
8.3 Colorectal Cancer 280
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2385276-colorectal-cancer-drug-development-pipeline-review-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +91 841 198 5042

Source URL: https://marketersmedia.com/colorectal-cancer-therapeutics-strategies-and-product-pipeline-review-2017/250073

For more information, please visit http://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 250073

Latest News

Xiaomi seeks to raise up to $6.1 billion in Hong Kong IPO

Jun 23, 2018

SEOUL, South Korea — Xiaomi Corp. plans to raise up to $6.1 billion in one of the biggest global stock market debuts in recent years as it tries to become a worldwide brand alongside Apple, Google and Amazon. The initial public offering in Hong Kong would value the Beijing-based company at as much as $70.3 billion, according to details released Saturday. Xiaomi will raise less than the $10 billion industry observers had expected, which would have valued the company at $100 billion. But it will still be among the biggest tech IPOs since Chinese e-commerce giant Alibaba raised $21.8 billion...

China blocks John Oliver on social media after scathing show

Jun 23, 2018

BEIJING — A popular Chinese social media site is censoring discussion of "Last Week Tonight" and its HBO host John Oliver after he mocked Chinese President Xi Jinping, his apparent sensitivity about being compared to Winnie the Pooh and his country's crackdown on human rights. Attempts to send posts with either the terms "John Oliver" or "Last Week Tonight" on the Sina Weibo microblog Friday were met with failure messages saying "the content contains information that violates relevant laws and regulations." Oliver's show on Sunday made satirical references to Xi and the way that Chinese internet users often joke that...

The Latest: Trump slams media coverage of North Korea summit

Jun 23, 2018

SEOUL, South Korea — The Latest on developments in inter-Korean relations after last week's landmark summit between U.S. President Donald Trump and North Korean leader Kim Jong Un (all times local): 11:55 p.m. U.S. President Donald Trump is continuing his assault on the media by suggesting that its coverage of the North Korea summit would have been more favorable had his predecessor done it. Trump tweeted Monday that "if President Obama...had gotten along with North Korea" and taken steps toward peace "the Fake News would have named him a national hero!" The president also asserted without evidence that his predecessor...

After summit, North Korea shows Trump in striking new light

Jun 23, 2018

PYONGYANG, North Korea — North Koreans are getting a new look at President Donald Trump. They see him shaking hands with Kim Jong Un at their historic summit in Singapore, and even awkwardly saluting a three-star general. It's a far cry from the "dotard" label their government slapped on him last year. Previously, even on a good day, the best he might get was "Trump." No honorifics. No signs of respect. Now, he's being called "the president of the United States of America." Or "President Donald J. Trump." Even "supreme leader." The post-summit transformation of North Korea's official version of...

China's Huawei says it hasn't collected Facebook user data

Jun 23, 2018

BEIJING — Chinese phone maker Huawei said Wednesday it has never collected or stored Facebook user data, after the social media giant acknowledged it shared such data with Huawei and other manufacturers. Huawei, a company flagged by U.S. intelligence officials as a national security threat, was the latest device maker at the center of a fresh wave of allegations over Facebook's handling of private data. Chinese firms Huawei, Lenovo, Oppo and TCL were among numerous handset makers that were given access to Facebook data in a "controlled" way approved by Facebook, according to a statement Tuesday from Francisco Varela, Facebook's...

Sign up now!